Spurious Medicines in India: Drug Quality, Traceability & Regulation

GS II: Issues relating to the development and management of Social Sector/Services relating to Health.

Context: The discovery of an unauthorised unit involved in the repackaging and distribution of expired and spurious medicines highlights vulnerabilities in India’s pharmaceutical supply chain and the need for stronger quality control, traceability and regulatory coordination.

Spurious and Substandard Drugs

• Spurious Drugs: Spurious drugs are medicines that are falsely represented, fraudulently manufactured or deceptively marketed, including products carrying misleading identities or claims.
• Active Pharmaceutical Ingredient: A medicine may be ineffective or dangerous if it lacks the required Active Pharmaceutical Ingredient (API) or contains an inappropriate substitute.
• Repackaging: Expired medicines can be illegally repackaged and marketed with altered labels or expiry dates.
• Counterfeit Branding: Genuine pharmaceutical brands may be imitated to sell inferior or unrelated products through deceptive packaging.

Best Online Coaching for UPSC

Public Health Implications

• Treatment Failure: Spurious medicines may fail to provide the intended therapeutic effect, resulting in deterioration of the patient’s condition.
• Patient Safety: Inadequate, contaminated or incorrect medicines can cause adverse health outcomes and fatalities.
• Antimicrobial Resistance: Substandard medicines containing inadequate quantities of active ingredients can contribute to the development of antimicrobial resistance (AMR).
• Loss of Trust: Counterfeit medicines undermine public confidence in doctors, hospitals, pharmacies and pharmaceutical manufacturers.
• Economic Burden: Treatment failure can increase out-of-pocket expenditure and impose additional costs on healthcare systems.

India as the Pharmacy of the World

• Generic Medicines: India is a major global producer and exporter of generic medicines and plays an important role in affordable pharmaceutical access.
• Global Supply Chains: Indian medicines reach numerous developing and developed markets, making domestic quality regulation relevant to global public health.
• Reputational Impact: Incidents involving poor-quality medicines can affect India’s pharmaceutical credibility and soft power.
• Quality over Volume: Sustaining India’s pharmaceutical leadership requires strong emphasis on quality assurance, regulatory compliance and patient safety.

Regulatory Challenges

• Multiple Authorities: Drug regulation involves the Central Drugs Standard Control Organisation (CDSCO) and State Drug Control Authorities, creating a need for effective coordination.
• Supply-Chain Gaps: Weaknesses in distribution and procurement systems can allow counterfeit products to enter legitimate pharmaceutical channels.
• Limited Traceability: Inadequate tracking makes it difficult to identify the origin and movement of suspicious medicines.
• Inspection Capacity: Regulatory agencies may face challenges relating to manpower, laboratory capacity and surveillance infrastructure.
• Procurement Vulnerabilities: Hospitals may face risks when procurement systems prioritise cost without adequate verification of suppliers and product authenticity.

UPSC Online Preparation

Technology-Based Solutions

• Track-and-Trace: Every medicine can be assigned a unique barcode or QR-based identity to facilitate verification across the supply chain.
• End-to-End Monitoring: Digital systems can track medicines from manufacturing and distribution to pharmacies and healthcare institutions.
• Blockchain: Blockchain-based systems can create tamper-resistant records of transactions and product movement.
• Digital Verification: Pharmacies, hospitals and consumers can use digital platforms to verify manufacturing details, batch information and authenticity.

Stronger Enforcement

• Integrated Regulation: Greater coordination between central and state drug regulators can improve enforcement and information sharing.
• Risk-Based Inspection: Manufacturing and distribution facilities should be prioritised for inspection based on risk indicators and past compliance records.
• Stronger Penalties: Deliberate manufacture and distribution of counterfeit medicines should attract effective and proportionate criminal penalties.
• Supply-Chain Accountability: Responsibility should extend beyond manufacturers to distributors, pharmacies and institutional procurement systems.
• Third-Party Audits: Independent audits can strengthen quality verification in the procurement systems of large healthcare institutions.

Way Forward

• National Drug-Quality Architecture: Strengthen coordination between central and state regulatory institutions.
• Universal Traceability: Expand technology-enabled track-and-trace mechanisms across the pharmaceutical supply chain.
• Testing Infrastructure: Increase the capacity and geographical reach of drug-testing laboratories.
• Digital Surveillance: Use data analytics to identify unusual distribution patterns and potential counterfeit networks.
• Inter-Agency Cooperation: Improve coordination among drug regulators, police, customs and cyber-investigation agencies.
• International Cooperation: Strengthen cross-border cooperation against organised networks involved in counterfeit pharmaceutical trade.

Click to Know UPSC Offline Courses

Conclusion

India’s ambition to remain the Pharmacy of the World requires equally strong systems of quality assurance, traceability and regulatory enforcement. Preventing spurious medicines is essential for protecting public health, strengthening trust in healthcare and sustaining India’s position in the global pharmaceutical sector.

Check Out UPSC CSE Books

Visit PW Store